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Abstract  
Background We aimed to compare the prevalence and severity of fatigue in survivors of 
Covid-19 versus non-Covid-19 critical illness, and to explore potential associations between 
baseline characteristics and worse recovery.  
Methods  We conducted a secondary analysis of two prospectively collected datasets. The 
population included was 92 patients who received invasive mechanical ventilation (IMV) with 
Covid-19, and 240 patients who received IMV with non-Covid-19 illness before the pandemic. 
Follow-up data was collected post-hospital discharge using self-reported questionnaires. The 
main outcome measures were self-reported fatigue severity and the prevalence of severe 
fatigue (severity >7/10) 3 to 12-months post-hospital discharge.  
Results Covid-19 IMV-patients were significantly younger with less prior comorbidity, and 
more males, than pre-pandemic IMV-patients. At 3-months, the prevalence (38.9% [7/18] vs. 
27.1% [51/188]) and severity (median 5.5/10 vs. 5.0/10) of fatigue was similar between the 
Covid-19 and pre-pandemic populations respectively. At 6-months, the prevalence (10.3% 
[3/29] vs. 32.5% [54/166]) and severity (median 2.0/10 vs. 5.7/10) of fatigue was less in the 
Covid-19 cohort. In the total sample of IMV-patients included (i.e. all Covid-19 and pre-
pandemic patients), having Covid-19 was significantly associated with less severe fatigue 
(severity <7/10) after adjusting for age, sex, and prior comorbidity (adjusted OR 0.35 (95%CI 
0.15-0.76, p=0.01). 
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Conclusion. Fatigue may be less severe after Covid-19 than after other critical illness. 
Introduction  
 
Post Intensive Care Syndrome (PICS) describes the constellation of physical, 
psychological and cognitive symptoms affecting 25% of critical illness survivors, which 
include fatigue, muscle weakness, and posttraumatic stress1. PICS may persist for longer 
than 5 years and is associated with high hospital resource use and readmission rates2.   
Implementation of post-ICU rehabilitation guidelines  is inconsistent, and the best ways to 
support intensive care unit (ICU) survivors are uncertain3–5; Identifying those at greatest risk 
of PICS and providing evidence-based strategies to enhance their recovery remain priorities 
for critical care research5. The Covid-19 pandemic heralded a dramatic increase in ICU 
admissions: in one study including over 20,000 UK hospitalised patients, 17% required 
admission to ICU or high dependency units , over half of whom survived to discharge, thus a 
vast new cohort of patients at risk of PICS has emerged6,7. This new cohort is relatively novel 
in terms of younger age, less previous comorbidity, and longer ICU stays than ICU 
admissions before the Covid-19 pandemic8,9.  
 
 Many patients who survive acute-Covid-19 experience persistent symptoms beyond 
4 weeks, known as ‘long-Covid’10. This includes a wide range of symptoms, such as 
breathlessness, fatigue, muscle pain, many of which overlap with PICS and other post-viral 
syndromes1,11–18. The most common symptom of long-Covid described following both 
community and hospital-managed acute-Covid-19 was fatigue: fatigue was reported in 
97.7% of community-managed cases who reported symptoms lasting over 28 days, and in 
83% and 98% of UK and China patients respectively greater than 3-months after hospital 
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discharge following admission with acute-Covid-1913,18,19. Recent studies have shown 
requiring invasive mechanical ventilation (IMV) is associated with experiencing worse 
fatigue and other recovery, but have not attempted to compare ‘long-Covid’ to recovery 
from all critical illness and were without control groups11,13,14.  
 
The prevalence of fatigue in ICU-survivors ranges from 13.8% to 80.9%20. This has a 
profound negative impact on survivors’ quality of life (QOL), and is one of the most 
prevalent and debilitating challenges of ICU-survivorship20,21.  Fatigue may lead to delayed 
return to employment and pre-critical illness physical fitness, difficulty in completing 
activities of daily living, social isolation, depression, and many other negative sequalae 20–22. 
It is unclear if recovery is different in survivors of Covid-19 critical illness compared to other 
critical illness, requiring distinct risk assessment tools or interventions to support their 
recovery.  
 
We aimed to characterise the prevalence and severity of fatigue in Covid-19 ICU-
survivors, compared to survivors of non-Covid-19 critical illness, and to explore potential 
associations between baseline characteristics and fatigue severity in these populations to 







Study design and population 
This was a secondary analysis of two prospectively collected datasets.  
 
Covid-19 cohort: International Severe Acute Respiratory Infection Consortium Coronavirus 
Clinical Characterisation Protocol - United Kingdom (ISARIC-4C CCP-UK):  
Patients aged 18 years and over, admitted to hospital between 17th January and 5th October 
2020 with confirmed or highly suspected SARS-CoV-2 infection at 31 UK centres, who 
consented to be contacted for follow-up studies, who completed a follow-up questionnaire, 
and who were discharged at least 90 days ago at the time of data collection were eligible for 
inclusion. Patients who did not survive to follow-up were excluded. We restricted this 
secondary analysis to patients who received IMV. 
 
Pre-pandemic cohort: Evaluation of a Rehabilitation Complex Intervention for Patients 
Following Intensive Care Discharge (RECOVER) trial:  
Patients aged 18 and over, discharged from ICU between 1st December 2010 and 31st 
January 2013 at 2 hospitals in Edinburgh, Scotland, who received a minimum of 48-hours of 
IMV23. Patients randomised to the intervention group received enhanced hospital and 
community-based physical rehabilitation, the control group received routine care23. Both 




Full details of the populations included in CCP-UK and RECOVER, and study information, 
have previously been published13,23.  
 
Clinical variables  
Both datasets captured demographic information, including age, sex, pre-existing 
comorbidities, admission diagnosis, length of hospital stay, and severity of acute illness. 
Comorbidities were defined in the ISARIC4C CCP-UK protocol for the Covid-19 cohort24, and 
by the Functional Comorbidity Index (FCI) for the pre-pandemic cohort23.  For the pre-
pandemic cohort, we combined ‘Angina’, ‘Congestive heart failure or heart disease’, and 
‘Heart Attack’ from the FCI under the heading ‘Chronic Cardiac Disease’ to compare to the 
Covid-19 cohort (for which this was a category in the ISARIC4C protocol); similarly 'Chronic 
Obstructive Pulmonary Disease’ on the FCI was compared to ‘Chronic Pulmonary Disease’.  
Diagnosis category was captured from the RECOVER data in order to stratify the RECOVER 
cohort by diagnosis, to  allow those with Respiratory diagnoses only to be compared to the 
Covid-19 cohort. Variables indicating acute illness severity differed: CCP-UK included ISARIC-
4C Mortality and World Health Organisation Severity Scores25,26; RECOVER included the 
Acute Physiology and Chronic Health Evaluation-II (APACHE-II) score27, duration of IMV, 
duration of ICU-admission, total and Respiratory Sequential Organ Failure Assessment 
(SOFA) scores28. Thus, and given the different underlying disease processes, acute illness 
severity, including duration of IMV and ICU admission, was not directly compared. RECOVER 
captured survival at 3, 6, and 12-months post-hospital discharge: patients alive at each 




Both studies used patient-completed questionnaires to collect outcome data13,23. CCP-UK 
completed follow-up assessment via postal questionnaires (or telephone where this was not 
possible), which patients completed once and returned13.  RECOVER completed follow-up 
assessment face-to-face or by telephone at 3-months, and by post at 6 and 12-months post-
hospital discharge23.  
 
In this secondary analysis, the primary outcome was patient-reported fatigue severity. 
Secondary outcomes were: ‘severe fatigue’, breathlessness, and measures of health-related 
QOL. 
 
In both studies, fatigue severity was measured using a 10-point Visual Analogue Scale (VAS), 
where zero is no fatigue and ten is worst possible fatigue. ‘Severe fatigue’ was defined as 
fatigue of at least 7/10 on the VAS.  
 
Statistical methods  
 
Covid-19 IMV-patients were compared to the pre-pandemic IMV-patients at baseline, 
follow-up, and potential associations with outcomes within each group were compared.  
 
Covid-19 and pre-pandemic IMV-patients, and the pre-pandemic subset with Respiratory 
diagnosis category, were compared at baseline in terms of age, sex, prior comorbidity, 
deprivation. Fatigue severity and the prevalence of severe fatigue was compared. Fatigue in 
Covid-19 IMV-patients was stratified by time since hospital discharge that patients 
responded to the CCP-UK questionnaire: approximately 3 (90-120 days) and 6-months (150-
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210 days), in order to compare fatigue at equivalent timepoints to that measured in the 
RECOVER study. Thus a smaller subset of the Covid-19 sample was compared to the pre-
pandemic group for fatigue at each timepoint. Fatigue severity (VAS scores) and ‘severe 
fatigue’ were compared as continuous and binary outcomes respectively.  
 
Where direct comparison was not possible, i.e. where the same variables measured with the 
same tools were not available in the two datasets, outcome variables from both datasets 
were presented separately. 
 
Categorical data were summarised as frequencies and percentages, continuous data as 
median and interquartile range (IQR). To test for differences across comparison groups in 
categorical data, we used Fisher’s exact test and for continuous data, using the Wilcoxon 
rank-sum test for two-sample testing and Kruskall-Wallis where there were more than 2 
groups. 
 
Using ordinal logistic regression and logistic regression, we explored if significant association 
existed between Covid-19 and severe fatigue in all patients included (Covid-19 and pre-
pandemic group), after adjustment for patient demographics (age, sex, presence of 
comorbidity). With ordinal regression we explored fatigue in categories: 0-2/10, 2-4/10, 4-
6/10, 6-8/10, 8-10/10, and with logistic regression we explored more severe reported 
fatigue, taking scores less than 7/10 or not as a binary outcome. Pre-pandemic outcomes at 
6 months were included. We repeated these regression analyses including the Covid-19 
group and the pre-pandemic subset with Respiratory diagnosis category. Effect estimates 
are presented as mean differences alongside 95% confidence intervals (95%-CI). Statistical 
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analyses were performed using R version 3.6.3 (R Foundation for Statistical Computing, 
Vienna, AUT) with the tidyverse, finalfit, eq5d and Hmisc packages. Statistical significance 





335 Covid-19 patients were included in the CCP-UK study:  27.5% (92/335) received IMV 
(Figure-1). 240 patients were included in RECOVER (pre-pandemic patients). A total of 332 
patients (92 Covid-19, 240 pre-pandemic patients) who received IMV were included in this 
secondary analysis (Figure-1). 29.2% [70/240] and 35.0% [84/240] of the pre-pandemic cohort 
were admitted with Cardiovascular and Respiratory diagnosis categories respectively (Table-
1).  
Covid-19 IMV-patients were significantly younger (median 59.7 years, IQR:51.1 to 64.5, 
p=0.017) than pre-pandemic IMV-patients (median 62.0 years, IQR:52.0 to 70.0, Table-1). A 
higher proportion of Covid-19 IMV-patients were males (70.7% [65/92]) than pre-pandemic 
(57.1% [137/240]). Significantly fewer Covid-19 IMV-patients had prior comorbidity (62.0% 
[57/92] vs 87.9% [211/240], p<0.001), and the median number of comorbidities was 
significantly lower (1, IQR:0 to 2 vs 2, IQR:1 to 4, p<0.001) Significantly fewer Covid-19 IMV-
patients had chronic pulmonary disease (5.8% [5/86] vs 15.4% [37/240], p=0.036). Both 
groups were similar in terms of socioeconomic status, and the prevalence of obesity, 
diabetes, chronic cardiac disease, and asthma. These associations were consistent when 
only Respiratory category pre-pandemic patients were included (Supplementary Table-1). 
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Covid-19 IMV-patients responded a median 185 days, IQR:137 to 241, after hospital 
discharge (Table-1).  
 
Pre-pandemic IMV-patients received a median 8 days of IMV, IQR:5 to 15; the median 
APACHE-II score was 20, IQR:16 to 25 (Table-1).  
 
Primary outcome 
The median fatigue severity reported by Covid-19 IMV-patients at the timepoint they 
responded was 5.0, (n= 85), IQR:2.0 to 7.0, Table-2). At 3-months, fatigue severity was similar 
between Covid-19 (n=18) and pre-pandemic IMV-patients (n=188). At 6-months, pre-
pandemic IMV-patients (n=166) reported significantly greater fatigue than Covid-19 IMV-
patients (n=29), median 5.7/10, IQR:3.5 to 7.3/10 vs median 2/10, IQR:1.0 to 5.0/10, p<0.001). 
These associations were again consistent when only Respiratory category pre-pandemic 
patients were included (Supplementary Table-2): at 3-months, fatigue severity was similar 
between Covid-19 (n=18) and Respiratory pre-pandemic IMV-patients (n=62); at 6-months, 
Respiratory pre-pandemic IMV-patients (n=54) reported significantly greater fatigue than 
Covid-19 IMV-patients (n=32), median 6.6/10, IQR:4.6 to 7.8/10, p<0.001.  Fatigue at 12-
months was not compared because Covid-19 IMV-patients had not accrued follow-up to this 
time point.  
 
Severe fatigue at the timepoint they responded was reported in 28.2% [24/85] of Covid-19 
IMV-patients who responded (Supplementary Table-3). At 3-months post-hospital discharge, 
the prevalence of severe fatigue was similar in Covid-19 (38.9%, [7/18]) and pre-pandemic 
IMV-patients (27.1%, [51/188]), and at 6-months significantly less Covid-19 IMV-patients 
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experienced severe fatigue (10.3% [3/29] vs 32.5% [54/166], p=0.015). This pattern was again 
consistent when only Respiratory category pre-pandemic patients were included 
(Supplementary Table-4): at 3-months and 6-months respectively, 35.5% [22/62] (p=0.789) 
and 44.4% [24/54] (p=0.0014) of Respiratory category pre-pandemic IMV-patients reported 
severe fatigue.  
 
Predictors of fatigue 
At a univariable level, in the Covid-19 group, females under 50 reported more severe fatigue 
(mean 5.20, 95%CI: 2.93 to 7.47); In pre-pandemic IMV-patients, sex did not affect outcomes 
(Supplementary Figure-1, Supplementary Table-5).   
 
In the total sample included (Covid-19 and pre-pandemic patients), having Covid-19 was 
significantly associated with less severe fatigue (cut-off 7/10, adjusted OR 0.35 (95%CI:0.15 
to 0.76, p=0.01) (Figure-2, Supplementary Table-5). When the Covid-19 IMV-patients and the 
Respiratory category pre-pandemic IMV-patients were included, having Covid-19 (adjusted 
OR 0.15, 95%CI:0.05 to 0.41) and female sex (adjusted OR 0.34, 95%CI:0.12 to 0.88) were 
significantly associated with less severe fatigue (Supplementary Figure-2, Supplementary 
Table-6). Ordinal logistic regression analysis showed that ventilated patients with Covid-19 
(adjusted OR 0.50, 95%CI:0.29to 0.84) had less severe fatigue than patients ventilated due to 
other aetiologies (total pre-pandemic cohort). One or more comorbidities (adjusted OR 3.17, 
95%CI:1.75 to 5.81) was associated with greater fatigue, and age 50-69 (adjusted OR 0.56, 
95%CI:0.29 to 1.05), and age over 70 (adjusted OR 0.39, 95%CI:0.18 to 0.84) were associated 
with less fatigue (Supplementary Table-7).  When the Covid-19 IMV-patients and the 
Respiratory category pre-pandemic IMV-patients were included, ordinal logistic regression 
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also showed that having Covid-19 (adjusted OR 0.29, 95%CI:0.13 to 0.58) was significantly 
associated with less severe fatigue (Supplementary Table-8); having prior comorbidity was 




We found a high prevalence and severity of patient-reported persistent fatigue 
following hospital discharge in ventilated patients with both Covid-19 and non-Covid-19 
critical illness. At 3-months post-hospital discharge, the prevalence and severity of fatigue 
reported was similar following Covid-19 and non-Covid-19 critical illness, however by 6-
months, patients ventilated for Covid-19 had significantly less severe fatigue than patients 
ventilated for other critical illness.   
 
Both Covid-19 and non-Covid-19 critical illness survivors experienced high levels of 
fatigue, adding to existing evidence that finding the best rehabilitation services to support 
ICU-survivors is a research priority4,5. In our study, the difference in fatigue prevalence and 
severity at 6-months suggests that the recovery trajectory from Covid-19 critical illness may 
be different to general PICS. Covid-19 critical illness survivors are also more likely to suffer 
additional respiratory sequelae29. In our analysis patients who survived Covid-19 were 
younger with less prior comorbidity than those surviving other critical illness - this may explain 
why less fatigue at 6-months was reported after Covid-19 critical illness, as coping with the 
challenges of comorbidity has been identified as a barrier to ICU-recovery30,31.  The lower 
fatigue in Covid-19 patients at 6-months is surprising as Covid-19 patients may have been 
expected to suffer worse fatigue than pre-pandemic patients if they were more likely to be 
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discharged at a lower functional level due to greater high-demand for ICU beds throughout 
the pandemic and a focus on survival as opposed to rehabilitation. A multitude of different 
factors interact to drive fatigue in critical illness survivors, including deconditioning secondary 
to extended immobilisation, anaemia, poor sleep, depression, post-traumatic stress, 
respiratory illness (which may be due to prolonged ventilation), chronic disease, and 
drugs1,20,30,32–35. It is possible that once acute illness severity exceeds the threshold for 
requiring IMV and ICU-admission, further illness severity and underlying disease have little 
impact on persistent fatigue. This is consistent with recent research which found that post-




Our data provides important insights into these complex syndromes, which need far 
greater research to assess the true impact they have on patients. To our knowledge, no 
previous study has included an appropriate control group with similar illness severity to a 
Covid-19 cohort. There are several important limitations to our study that must be 
considered. Firstly, our findings may be subject to responder and survivor bias. The sample 
sizes included by both CCP-UK and RECOVER were relatively small, with the RECOVER 
sample being substantially larger, and individuals with milder symptoms may have felt less 
compelled to respond, and those with the most severe symptoms or who died would have 
been unable to respond. Self-reported fatigue may have been affected by patients’ 
perceptions of their function or fatigue level prior to ICU admission, which may be affected 
by their age or previous comorbidities. As the Covid-19 group was significantly younger with 
less comorbidity, and therefore may have had a self-perceived lower baseline fatigue, an 
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ideal study would have compared more objective measurements of fatigue level. Secondly, 
the overall Covid-19 cohort was included in our logistic regression models, which may have 
introduced bias from differing questionnaire response times post-hospital discharge. 
However, we controlled for CCP-UK and RECOVER measuring outcomes at different 
timepoints by stratifying fatigue by time since hospital discharge when comparing fatigue 
prevalence and severity, which allowed equivalent timepoints to be compared but further 
restricted Covid-19 sample sizes, therefore limiting the external validity of our findings to 
the general ICU population. Thirdly, our results may not be fully representative of all 
survivors of Covid-19 or non-Covid critical illness, as only patients admitted to a few UK 
hospitals were included (31 hospitals were included in CCP-UK and only 2 in RECOVER, 
therefore CCP-UK is likely to have captured a much wider variation in population and 
recovery services available to the patients included). Forthly, as CCP-UK and RECOVER did 
not use the same outcome measures, we were unable to explore differences in indicators of 
acute illness severity, including duration of IMV and length of ICU stay,  between Covid-19 
and pre-pandemic patients, which may have been an important risk factor for fatigue and 
therefore confounded our results, however a recent systematic review found no significant 
difference in mortality, length of hospital stay, or IMV-free days between Covid-19 and the 
general Acute Respiratory Distress Syndrome population37. Also, pre-critical illness factors, 
such as prior comorbidity, may be stronger predictors of hospital readmission and resource 
use than acute illness factors in ICU survivor patients31. An ideal study design would have 
used retrospective measurements of pre-critical illness functional levels, utilised repeated 
measures (much like the RECOVER study) of those with Covid-19 ,and would also feature a 
non-Covid-19 contemporaneous control group, to control for other factors which may 
impact post-ICU recovery, such as the ‘lockdown’ restrictions in place during CCP-UK’s study 
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period;  restrictions such as office closures may have meant survivors’ lives were less 
physically demanding, allowing for greater rest, and the pandemic has heralded the 
formalisation of ICU-recovery clinics in some areas38. As the RECOVER study was completed 
8 years prior to CCP-UK, the level of follow-up care available is likely to have changed over 
this time prior to the Covid-19 pandemic, particularly as rehabilitation after critical illness 
was made a NICE quality standard in 2017, recommending a review at 2-3 months post ICU-
discharge4. 
 
We found high levels of fatigue following both Covid-19 and non-Covid-19 critical 
illness. Survivors of Covid-19 critical illness experienced less severe fatigue at 6-months post-
hospital discharge than survivors of non-Covid-19 critical illness, potentially due in part to the 
comparatively younger and less comorbid Covid-19 ICU cohort versus the non-Covid-19 
cohort. Research targeting interventions to best support critical illness survivors is required 
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Table 1: Patient characteristics of Covid-19 (n=92) and pre-pandemic IMV-patients (n=240).  
IQR – Interquartile range, presented as 25th to 75th centiles. Numbers are presented as N (%), unless otherwise denoted as a 
continuous variable. ICU – Intensive Care Unit. IMV – Invasive Mechanical Ventilation. SOFA – Sequential Organ Failure 
Assessment. APACHE-II – Acute Physiology and Chronic Health-II.  
  Covid-19 cohort Pre-pandemic cohort p-value 
Total N (%)  92 (27.7) 240 (72.3)  
Age Median (IQR) 59.7 (51.1 to 64.5) 62.0 (52.0 to 70.0) 0.017 
Sex Male 65 (70.7) 137 (57.1) 0.032 
 Female 27 (29.3) 103 (42.9)  
Number of comorbidities Median (IQR) 1.0 (0.0 to 2.0) 2.0 (1.0 to 4.0) <0.001 
Comorbidities or not No comorbidities 35 (38.0) 29 (12.1) <0.001 
 One or more comorbidities 57 (62.0) 211 (87.9)  
Deprivation Most deprived 1 10 (10.9) 33 (13.8) 0.277 
 2 19 (20.7) 60 (25.0)  
 3 26 (28.3) 48 (20.0)  
 4 22 (23.9) 45 (18.8)  
 Least deprived 5 15 (16.3) 54 (22.5)  
Obesity No 62 (72.9) 187 (77.9) 0.434 
 Yes 23 (27.1) 53 (22.1)  
Diabetes No 66 (75.9) 203 (84.6) 0.097 
 Yes 21 (24.1) 37 (15.4)  
Asthma No 71 (82.6) 197 (82.1) 1.000 
 Yes 15 (17.4) 43 (17.9)  























ICU admission diagnosis 
category 
Cardiovascular - 70 (29.2) - 
 Respiratory 92 (100.0) 84 (35.0) - 
 Gastrointestinal tract - 59 (24.6) - 
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  Covid-19 cohort Pre-pandemic cohort p-value 
 Renal - 3 (1.3) - 
 Trauma - 8 (3.3) - 
 Neurologic  12 (5.0)  
 Miscellaneous diagnoses - 4 (1.7) - 
ISARIC-4C Mortality Score Median (IQR) 8.0 (5.0 to 10.0) - - 
Length of hospital stay Median (IQR) 
26.0 (15.5 to 40.0) 32.0 (20.0 to 50.0) 
0.02 
ICU length of stay Median (IQR) - 11.0 (6.8 to 18.0) - 
Duration of IMV Median (IQR) - 8.0 (5.0 to 15.0) - 
Total SOFA Score Median (IQR) - 3.0 (2.0 to 4.0) - 
Respiratory SOFA Score 0 - 23 (9.6) - 
 1  73 (30.4)  
 2  144 (60.)  
APACHE-II Score Median (IQR) - 20.0 (16.0 to 25.0) - 
Time from discharge to 
completing CCP-UK 
questionnaire (days) 
Median (IQR) 185.0 (136.8 to 241.2) - - 
3-month survival Yes  - 216 (94.7) - 
 No  12 (5.3)  
6-month survival Yes  - 169 (89.4)  
 No  20 (10.6)  
12-month survival Yes - 163 (88.1)  







Table 2: Fatigue severity in Covid-19 and pre-pandemic IMV-patients. 
  Covid-19 cohort Pre-pandemic cohort p-value 
Total N  18  188   
Fatigue severity at ~3 
months 
Median (IQR) 5.5 (2.0 to 6.2) 5.0 (2.8 to 7.0) 0.809 
Total N   32  166  
Fatigue severity at ~6 
months 
Median (IQR) 2.0 (1.0 to 5.0) 5.7 (3.5 to 7.3) <0.001 
Total N   -  159  
Fatigue severity at ~12 
months 
 -  5.0 (3.0 to 7.0) -  
Total N  85 -   
Fatigue severity across 
follow-up period 
Median (IQR) 5.0 (2.0 to 7.0) -  -  
Fatigue severity according to Visual Analogue Scale in self-reported questionnaires. Covid-19 cohort: ~3 months – 90-120 
days, ~6 months – 150-210 days, Fatigue at 12 months was not compared as the Covid-19 cohort had not accrued follow-up 































Figure 2: Logistic regression model for severe (>=7/10) fatigue at 6-months including all 
patients (Covid-19 and pre-pandemic group). OR, 95% CI, p-value. Pre-pandemic patients included 
at 6-months follow-up. Number in model = 251,  AIC = 262.4, C-statistic = 0.676, H&L = Chi-sq(8) 2.26 (p=0.972) Group = 
Covid-19 status. 0= pre-pandemic group, non-Covid. 1= Covid-19 cohort. No_comorbid_factor = Number of comorbidities. 
Male, Group 0, No Comorbidities, Age Under 50 are marked with ‘-‘ as these were used as the reference level for each 
respective variable.  
 
 
 
 
 
 
 
 
 
 
 
 
 
